Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. Check out my ...
A color vision test shows good correlation with cone and cone-rod dystrophy biomarkers and may offer a cost-effective replacement for ERG.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback